A total of 709 patients were enrolled in CheckMate 274, including 353 patients (of whom 140 patients had PD-L1 ≥ 1%) who were randomly assigned to take nivolumab 240 mg every 2 weeks ...
patients were randomized 1:1 to receive IV nivolumab or placebo 240 mg every 2 weeks for up to a year of adjuvant treatment. Patients were stratified by tumor PD-L1 expression, nodal status ...
The study enrolled 64 patients with treatment-naïve metastatic melanoma between March 2017 and July 2019. Participants ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback